Soluble amphotericin B and clotrimazole with protein carrier for yeast infection treatment
Spectral Platforms offers a novel protein-based aqueous solution of Clotrimazole and Amphotericin B for over-the-counter yeast infection treatment. This formulation enhances anti-fungal efficacy and biofilm disruption by leveraging a protein carrier for improved microorganism binding.
Overview
Spectral Platforms introduces an innovative protein-based formulation that transforms water-insoluble anti-fungal agents, Clotrimazole and Amphotericin B, into a water-soluble solution. This groundbreaking product is designed for the over-the-counter treatment of yeast infections, providing enhanced efficacy by targeting and disrupting Candida biofilms. The unique formulation utilizes a protein carrier with preferential binding to microorganisms, thereby increasing the killing efficiency of the anti-fungal agents.
Technical specifications
- Protein carrier technology: Utilizes a protein that renders water-insoluble compounds such as Amphotericin B soluble in aqueous solutions.
- Enhanced efficacy: Documented in-vitro results show a 3X reduction in minimum inhibitory concentration (MIC), allowing lower concentrations of anti-fungal agents to effectively suppress Candida growth.
- Biofilm disruption: Designed to be applied during a bath, the solution selectively disrupts Candida biofilms, leveraging the protein carrier's affinity for metabolically active microorganisms.
Technology readiness level
This solution is at Technology Readiness Level 5, indicating that it has been validated in a relevant environment and is undergoing further optimization to investigate the most effective combinations and concentrations of anti-fungal agents for complete biofilm disruption.
About Spectral Platforms
Spectral Platforms is a biotechnology company focused on developing rapid diagnostic solutions for clinical microbiology. The company has created proprietary technology that detects bacterial pathogens by measuring metabolic markers and redox state changes in clinical samples. This approach aims to bypass traditional, time-consuming culture methods, offering diagnostic results for bacteria presence within 30 minutes. By enabling faster identification and antimicrobial susceptibility testing (AST), the platform is designed to provide actionable data for clinicians to initiate effective antibiotic therapy significantly earlier than current standards allow.
This technology is primarily intended for use in triaging patients at risk of sepsis and managing infectious diseases. By providing rapid and reliable results, including AST results for both single and poly-microbial samples, the company seeks to improve patient outcomes and optimize clinical decision-making. Founded in 2010 and based in Duarte, California, Spectral Platforms engages in research and development for the medical diagnostics industry, often working within the healthcare, biotechnology, and life sciences sectors to validate its diagnostic innovations for clinical environments.
delivered to your inbox.